Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Oct 15, 2019

BUY
$1.34 - $2.4 $5,360 - $9,600
4,000 New
4,000 $6,000
Q2 2019

Aug 06, 2019

SELL
$1.46 - $4.44 $4,380 - $13,320
-3,000 Closed
0 $0
Q1 2019

May 01, 2019

BUY
$3.41 - $4.57 $10,230 - $13,710
3,000 New
3,000 $11,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $559M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Sterling Investment Advisors, Ltd. Portfolio

Follow Sterling Investment Advisors, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sterling Investment Advisors, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Sterling Investment Advisors, Ltd. with notifications on news.